Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some of the key technical challenges in this field.
|Original language||English (US)|
|Number of pages||2|
|Journal||Nature Reviews Drug Discovery|
|State||Published - Jun 1 2017|
ASJC Scopus subject areas
- Drug Discovery